EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of EXCEMED. All presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
David Bates Declared receipt of honoraria or consultation fees from Bayer, Biogen, Sanofi, Merck Serono.
Roberto Bergamaschi Declared receipt of grants and contract from Merck Serono, Bayer, Biogen, Genzyme, Novartis, Sanofi, Teva. He declared receipt of honoraria or consultation fees from Merck Serono, Bayer, Biogen, Genzyme, Novartis, Sanofi, Teva. He declared to be member of these company advisory boards, board of directors or other similar boards: Bayer, Biogen.
Saeed Bohlega Declared receipt of grants and contracts from Merck Serono. He declared receipt of honoraria or consultation fees from Biogen and Novartis.
Giancarlo Comi Declared receipt of honoraria or consultation fees from: Novartis, Teva, Genzyme, Merck Serono, Bayer, Biogen, Actelion, Almirall.
Nicola De Stefano Declared receipt of honoraria or consultation fees from Novartis, Merck Serono, Teva, Biogen, Sanofi Aventis. He declared to be member of these company advisory boards, board of directors or other similar boards: Novartis, Merck Serono. He declared participation in a company sponsored speaker’s bureau: Novartis, Merck Serono, Biogen Idec, Teva, Bayer, Sanofi-Aventis.
Giles Edan Declared receipt of grants and fees from Merck Serono,Teva, Biogen Idec, Novartis, Sanofi.
Robert Fox Declared receipt of grants and contract from Biogen Idec, Novartis. He declared receipt of honoraria or consultation fees from: Allozyne, Biogen Idec, Novartis, Teva, Xenoport.
Jihad Inshasi Declared no potential conflicts of interest
Dawn Langdon Declared receipt of grants and contracts from Bayer, Biogen, Novartis. She declared also receipt of honoraria or consultation fees from Bayer, Novartis, Merck Serono.
Letizia Leocani Declared no potential conflict of interest.
Filippo Martinelli Boneschi Declared receipt of honoraria or consultation fees from Biogen-Idec, Merck Serono.
Vittorio Martinelli Declared receipt of grants and contracts from Merck Serono. He declared also receipt of honoraria or consultation fees from Merck Serono, Sanofi Aventis, Biogen Idec, Teva, Novartis, Bayer. He declared to be member of a company advisory board, board of directors or other similar groups: Merck Serono, Bayer, Sanofi Aventis.
Carlo Pozzilli Declared to be member of scientific advisory boards: Novartis, Merck Serono, Biogen Idec, Sanofi-Aventis, Genzyme, Almirall and Bayer Schering. He received funding and honoraria from Novartis, Merck Serono, Biogen Idec, Sanofi-Aventis, Genzyme, Almirall, Bayer Schering, Actelion, Teva. He received research support from Novartis, Merck Serono, Biogen Idec, Bayer Schering and Sanofi-Aventis.
Peter Rieckmann Declared receipt of honoraria or consultation fees from Bayer, Biogen Idec, Boehringer, Pfizer, Merck Serono, Genzyme, Teva, Novartis.
Maria Assunta Rocca Declared participation in a company sponsored speakers’ bureau: Biogen, Merck Serono, Novartis.
Mohammad Ali Sahraian Declared no potential conflict of interest.
Aksel Siva Declared receipt of grants and contract from the Scientific and Technological Research Council of Turkey. He declared receipt of honoraria or consultation fees from: Novartis, Biogen.
Alessandra Solari Declared receipt of honoraria or consultation fees from: Novartis, Genzyme. She declared to be member of these company advisory boards, board of directors or other similar boards: Novartis.
Mar Tintoré Declared receipt of honoraria or consultation fees from Biogen, Merck Serono, Novartis, Genzyme. She declared to be member of these company advisory boards, board of directors or other similar boards: Genzyme, Biogen.
Bassem Yamout Declared receipt of grants and contract from Merck Serono. He declared receipt of honoraria or consultation fees from Merck Serono, Novartis, Biogen Idec, Genzyme. He declared to be member of these company advisory boards, board of directors or other similar boards: Merck Serono, Novartis, Biogen Idec, Genzyme.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 22 April 2014.
Raed Alroughani, Orhan Aktas, Isa Al Sharoqi, Ilham Slassi